来凯医药-B(02105)涨超9%，公司完成配售净筹约5.77亿港元，拟用于推进ActRII产品组合开发。 小鹏汽车-W(09868)再涨超6%,，小鹏宣布进入欧洲五国市场，奥地利工厂首批新车量产下线。 智通财经APP获悉，港股恒生指数跌0.65%，跌171点，报26312点；恒生科技指数跌1.04%。港股早盘成 交1655亿港元。 摩根士丹利上调中国风电行业评级，其认为反内卷努力后板块或迎来复苏。风电股逆市走高，金风科技 (02208)涨4.6%，大唐新能源(01798)涨超1.5%。 内房股集体拉升，北上深此前优化地产政策，多个新一线城市正谋划激发改善性住房需求新政。龙湖集 团(00960)涨2.3%；万科企业(02202)涨2.42%；碧桂园(02007)涨3.5%。 华虹半导体(01347)涨4.8%创新高，近期宣布与华力微重组，高盛称公司已与客户谈判涨价。 网龙(00777)一度涨超13%，公司多款游戏将于下半年上线海外，核心IP优化后有望实现增长。 博雷顿（01333）涨超20%，与一矿业建设集团签署战略合作，推进矿山运输智能化发展。 方舟健客(06086)涨超7%，杏石医疗大模型登上Nature ...

据了解，作为方舟健客的"超级数字大脑"，杏石大模型驱动着AI用药助手、AI健康管家、AI医生助 手、AI学术助手和AI搜索5大应用。每款应用可分别针对临床与患者端的特定场景，在诸如用药指导、 患者教育、诊断辅助及医学文献查询等领域实现实时精准辅助。例如，AI学术助手产品通过搭配语音 交互功能支持专家级答案秒级语音播报，契合临床医生忙碌的诊疗场景，提升了工具使用效率和黏性。 报道指出，近年来以大模型为代表的新一轮AI技术浪潮兴起。方舟健客也及时捕捉到了行业发展趋 势，并开展了相应探索。今年9月，方舟健客杏石大模型正式落地，不仅吸引到医疗领域的关注，其创 新模式更被国外学者敏锐捕捉，首次登上了Nature报道。 智通财经APP获悉，方舟健客(06086)涨超8%，截至发稿，涨8.23%，报4.34港元，成交额4077.62万港 元。 消息面上，据动脉网报道，近日，Nature的新闻版面刊登了一则关于中国医疗大模型的报道，引发行业 广泛关注。Nature报道中所提及的中国慢病管理模式，是全球范围内较少的、将AI与多种慢性疾病管理 深度融合且取得较好成绩的典型案例。目前海外市场中，将AI+多种慢病管理深度融合且有较大 ...

Group 1 - The core viewpoint of the articles highlights the significant rise of Ark Health (方舟健客) stock, which increased by 8.23% to HKD 4.34, with a trading volume of HKD 40.77 million, following a report in Nature about China's medical AI models [1] - The Nature report emphasizes China's chronic disease management model, which integrates AI with various chronic disease management practices, showcasing a successful case that is rare globally [1] - The report indicates that while there are few large-scale companies in the overseas market that deeply integrate AI with chronic disease management, China's innovative forces are emerging in this field, potentially allowing for a leapfrog development [1] Group 2 - Ark Health's "super digital brain," the Xing Shi model, drives five major applications: AI medication assistant, AI health manager, AI doctor assistant, AI academic assistant, and AI search, each tailored for specific clinical and patient scenarios [2] - Each application provides real-time and precise assistance in areas such as medication guidance, patient education, diagnostic support, and medical literature queries [2] - The AI academic assistant product enhances efficiency and user engagement by offering expert-level answers with voice interaction capabilities, catering to the busy clinical environment of doctors [2]

Group 1 - Ark Health (6086.HK), known as the "first stock in AI chronic disease management," saw its stock price surge by 21.95% to HKD 5, reaching a new high since May 2 of this year [1] - For the first half of 2025, Ark Health reported revenue of HKD 1.494 billion, a year-on-year increase of 12.9%, and net profit turned positive at HKD 12.5 million, with adjusted net profit reaching a record high of HKD 17.6 million, up 16.8% year-on-year [1] - The company achieved significant progress in its core business, with online retail pharmacy service revenue of HKD 864 million, a substantial increase of 28.2% year-on-year, and comprehensive medical service revenue of HKD 357 million, up 11.4% year-on-year [1] Group 2 - Cinda Securities reported that Ark Health's net profit for the first half of 2025 turned positive, with expectations for performance and AI layout breakthroughs in the second half of 2025 [2] - As a leading online chronic disease management platform in China, the company has over 11 million monthly active users and a repurchase rate of 85% [2] - The company has deployed an "AI Diagnosis Assistant" to help patients select doctors and appropriate departments, launched an "AI Doctor Assistant" to support doctors in diagnosis and treatment, and upgraded its "AI Customer Service Assistant" for better medication management support [2] - Cinda Securities projects the company's revenue for 2025-2027 to be approximately HKD 3.334 billion, HKD 4.038 billion, and HKD 4.901 billion, with year-on-year growth rates of about 23%, 21%, and 21% respectively, and net profits of HKD 16 million, HKD 36 million, and HKD 62 million, with year-on-year increases of approximately 102%, 119%, and 73% respectively [2]

Core Insights - Ark Health (6086.HK), known as the "first stock in AI chronic disease management," saw its stock price surge by 9% to HKD 4.22, with a total market capitalization of HKD 5.66 billion [1] Financial Performance - For the first half of 2025, the company reported revenue of HKD 1.494 billion, representing a year-on-year growth of 12.9% [1] - The net profit turned from loss to profit, reaching HKD 12.5 million, while the adjusted net profit hit a record high of HKD 17.6 million, up 16.8% year-on-year [1] User Engagement and Growth - The company has over 11 million monthly active users with a repurchase rate of 85% [1] - As of the first half of 2025, the platform registered 52.8 million users, with an average of 11.9 million monthly active users over the twelve months ending June 30, 2025 [1] - The repeat purchase rate for paying users stands at 85.4% [1] AI Integration and Business Model - The company has deployed an "AI consultation assistant" to help patients select doctors and appropriate departments, and launched an "AI doctor assistant" to provide diagnostic support to physicians [1] - Additionally, the company upgraded its "AI customer service assistant" to enhance medication management for patients throughout their treatment journey [1] - This innovative business model aims to continuously improve physician efficiency and manage patients throughout their entire lifecycle [1]

Core Viewpoint - Ark Health (6086.HK), known as the "first stock in AI chronic disease management," saw its stock price rise over 16% to HKD 4.35, reaching a nearly four-month high [1] Financial Performance - For the first half of 2025, Ark Health reported revenue of HKD 1.494 billion, a year-on-year increase of 12.9% [1] - The company achieved a net profit of HKD 12.5 million, marking a turnaround from previous losses [1] - Adjusted net profit reached a new high of HKD 17.6 million, up 16.8% year-on-year [1] Business Segments - Revenue from online retail pharmacy services amounted to HKD 864 million, showing a significant year-on-year growth of 28.2% [1] - Comprehensive medical services generated revenue of HKD 357 million, reflecting an 11.4% year-on-year increase [1] Analyst Coverage - Citigroup initiated coverage on Ark Health, highlighting the company's strong long-term doctor-patient relationships and a loyal, active paying user base [1] - The firm noted high user repurchase rates and strong willingness to pay, assigning a "Buy" rating with a target price of HKD 8.5 [1]

Core Viewpoint - Le Xin Medical has shown significant improvement in profitability and cash flow in the first half of 2025, with positive developments in AI digital chronic disease management [1][2]. Financial Performance - In the first half of 2025, Le Xin Medical achieved operating revenue of 521 million yuan, a year-on-year increase of 4.57% [1]. - The net profit attributable to shareholders reached 42.29 million yuan, up 21.35% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was 38.07 million yuan, reflecting a year-on-year growth of 17.57% [1]. - The net cash flow from operating activities increased by 46.80%, amounting to 48.25 million yuan [1]. Business Development - The company is building a comprehensive health management ecosystem based on "hardware + data + AI + services" [1]. - In the consumer medical device sector, Le Xin Medical continues to expand its product range, including electronic blood pressure monitors, body fat scales, blood glucose meters, and smart wristbands, while collaborating with international brands like Braun and Philips [1]. Remote Health Management - Le Xin Medical's remote health management (RPM) sector is steadily developing, with ongoing services for key clients such as Teladoc and Livongo [2]. - The company has made substantial progress in AI digital chronic disease management, particularly in cardiovascular disease risk screening and remote ECG services, establishing a complete technical chain from data collection to AI intervention [2]. Research and Development - In the first half of 2025, Le Xin Medical continued to invest in R&D for smart rings, multi-lead ECG machines, and remote blood glucose meters, aiming for a diversified and comprehensive health monitoring scenario [2]. - The company has achieved technical milestones in AI algorithms for chronic disease intervention, focusing on cardiovascular models, CMR image generation, and atrial fibrillation screening [2]. Shareholder Returns - The company proposed a mid-term profit distribution plan, intending to distribute a cash dividend of 1.30 yuan (tax included) for every 10 shares, with a total expected dividend of approximately 28.25 million yuan [2]. Future Outlook - Le Xin Medical aims to leverage its synergies in smart hardware, data integration, and AI algorithms to expand market coverage and solidify its dual-driven business development model of "smart health + medical services" [2].